Human WWOX gene encodes a proapoptotic WW domaincontaining oxidoreductase WOX1 (also named WWOX, FOR2 or WWOXv1). Apoptotic and stress stimuli activate WOX1 via Tyr33 phosphorylation and nuclear translocation. WOX1 possesses a tetrad NSYK motif in the Cterminal short-chain alcohol dehydrogenase/reductase (SDR) domain, which may bind estrogen and androgen. Here, we determined that 17b-estradiol (E 2 ) activated WOX1, p53 and ERK in COS7 fibroblasts, primary lung epithelial cells, and androgen receptor (AR)-negative prostate DU145 cells, but not in estrogen receptor (ER)-positive breast MCF7 cells. Androgen also activated WOX1 in the AR-negative DU145 cells. These observations suggest that sex hormone-mediated Tyr33 phosphorylation and nuclear translocation of WOX1 is independent of ER and AR. Stress stimuli increase physical binding of p53 with WOX1 in vivo. We determined here that E 2 increased the formation of p53/WOX1 complex and their nuclear translocation in COS7 cells; however, nuclear translocation of this complex could not occur in MCF7 cells. By immunohistochemistry, we determined that progression of prostate from normal to hyperplasia, cancerous and metastatic stages positively correlate with upregulation and activation of WOX1 and WOX2 (FOR1/WWOXv2). In contrast, breast cancer development to a premetastatic state is associated with upregulation and Tyr33 phosphorylation of cytosolic WOX1 and WOX2, followed by significant downregulation or absent expression during metastasis. These Tyr33-phosphorylated proteins are mostly located in the mitochondria without translocating to the nuclei, which is comparable to those findings in cultured breast cancer cells. Together, sex steroid hormone-induced activation of WOX1 and WOX2 is independent of ER and AR, and this activation positively correlates with cancerous progression of prostate and breast to a premetastatic state.
Introduction
WW domain-containing oxidoreductase WOX1, also known as WWOX or FOR2 (WWOXv1, GenBank's nomenclature), was independently isolated by three laboratories (Bednarek et al., 2000; Ried et al., 2000; Chang et al., 2001) . WWOX gene encodes this protein. WOX1 has been shown to be a candidate tumor suppressor and a proapoptotic protein (Richards, 2001; Chang, 2002a; Chang et al., 2003b; reviews) . The full-length WOX1 possesses two N-terminal WW domains (containing conserved tryptophan residues), a nuclear localization sequence (NLS), and a C-terminal short-chain alcohol dehydrogenase/reductase (SDR) domain (Chang et al., 2003b) . There are at least eight alternatively transcribed mRNAs of WWOX gene (Chang et al., 2003b) . Whether these transcripts can be translated successfully into proteins are unknown.
Murine WOX1 was isolated by functional cloning from hyaluronidase PH-20-treated L929 fibroblasts and shown to enhance the cytotoxic function of tumor necrosis factor (TNF) (Chang et al., 2001) . Hyaluronidases Hyal-1 and Hyal-2 also induce the expression and enhance the apoptotic function of WOX1 (Chang, 2002b) . WOX1 physically interacts with p53 and both proteins induce cell death synergistically (Chang et al., 2001) . We have determined that antisense WOX1 mRNA and a dominant negative WOX1 inhibit p53 apoptosis, indicating an important functional relationship for p53 and WOX1 (Chang et al., 2001 (Chang et al., , 2003a . This relationship has been further confirmed using siRNA-targeting WOX1 (Chang et al., unpublished) . Most recently, we determined that UV and anisomycin induce WOX1 activation, via phosphorylation at tyrosine 33 (Tyr33) and nuclear translocation (Chang et al., 2003a) . Abrogation of Tyr33 phosphorylation by mutating this amino-acid residue inhibits WOX1 nuclear translocation (Chang et al., 2003a) . Similarly, alteration of charged amino acid residues in the nuclear localization sequence (NLS) results in inhibition of WOX1 nuclear translocation and its-mediated apoptosis (Chang et al., 2001 (Chang et al., , 2003a .
WOX1 belongs to the SDR-containing protein family, which has more than 2000 protein members (Kallberg et al., 2002; review) . Majority of these SDR enzymes possess a catalytic tetrad of NSYK (Asn-Ser-Tyr-Lys) (Filling et al., 2002) . SDR proteins mediate oxidation/ reduction of lipid hormones and metabolic mediators (Kallberg et al., 2002) . Based on computer simulation, this NSYK motif in human WOX1 is determined to be N232, S281, Y293, and K297 (Chang et al., 2003a) . WOX1 and its isoform WOX2 (FOR1/WWOXv2) are likely to bind sex hormones such as androgen and estrogen via its NSYK motif.
Results

17b-estradiol (E 2 ) induces Tyr33 phosphorylation and nuclear translocation of WOX1 and WOX2 in COS7 fibroblasts
We determined whether androgen and estrogen activate WOX1. When COS7 fibroblasts were exposed to various amounts of 17b-estradiol (E 2 , 10-160 nM) for 1 h, the level of WOX1 was reduced in the cytosol, but increased in the nuclei (Figure 1a ), indicating that E 2 induces WOX1 nuclear translocation. Similarly, the extent of Tyr33 phosphorylation in WOX1 was reduced in the cytosol, but increased in the nucleus (Figure 1a) . Immunostaining further verified the presence of WOX1 in the nuclei of E 2 -stimulated cells (Figure 1a ). In parallel, there were increased levels of phosphorylated p53 (at Ser15) and extracellular regulated kinase (ERK; at Tyr204) in the nuclei ( Figure 1a ). E 2 is known to activate ERK (Keshamouni et al., 2002; Setalo et al., 2002) .
In a time course experiment, E 2 rapidly induced nuclear translocation of WOX1 and its isoform WOX2 (FOR1), during exposure of COS7 cells to E 2 for 20 min ( Figure 1a ). COS7 is an SV40-transformed cell line, expressing wild-type p53. Similarly, in nontransformed primary mink lung epithelial Mv1Lu cells, E 2 stimulated phosphorylation and nuclear translocation of both endogenous WOX1 and p53 in a time-dependent manner ( Figure 1b) . Note that compared to the levels of WOX1, p53 is overexpressed in COS7 cells, but not in Mv1Lu cells.
Next, we tested the specificity of E 2 in activating WOX1. Both 6-ketoestradiol and E 2 had similar effects on inducing WOX1 activation (data not shown). Compared to 6-ketoestradiol and E 2 , estriol had less effect in activating WOX1 (B50% reduction in nuclear WOX1 phosphorylation). The results indicate that 'diol' in estrogen is critical in activating WOX1.
The quality of our newly developed antibodies against GST-tagged WOX1, along with our previously described antibodies against WOX2 (Sze et al., 2004) and Tyr33-phosphorylated WOX1 (p-WOX1) (Chang et al., 2003a) , is shown in the Supplementary Information (Supplementary Figure 1) .
Dominant-negative WOX1 abolishes E 2 -mediated WOX1 activation in COS7 cells
We have previously developed a dominant-negative WOX1 (dn-WOX1) and shown to block p53 apoptosis and anisomycin-induced WOX1 phosphorylation at Tyr33 (Chang et al., 2003a) . Transient expression of GFP-tagged dn-WOX1 blocked E 2 -induced phosphorylation and nuclear translocation of WOX1 and p53 in COS7 cells (Figure 1c ; data not shown for phosphorylation). Tyr33-phosphorylation is essential for WOX1 nuclear translocation (Chang et al., 2003a) . Expression of the ectopic GFP-dn-WOX1 or GFP alone in COS7 Figure 1 17b-estradiol (E 2 ) stimulates phosphorylation and nuclear translocation of WOX1, p53 and ERK in COS7 fibroblasts and Mv1Lu epithelial cells. (a) Stimulation of COS7 fibroblasts with E 2 (10-160 nM) for 1 h resulted in activation of WOX1 via Tyr33 phosphorylation (p-WOX1) and nuclear translocation. By cell immunostaining, presence of Tyr33-phosphorylated WOX1 in the nuclei was observed in E 2 -treated cells. Similarly, E 2 induced phosphorylation of nuclear p53 (at Ser15) and ERK (at Tyr204). E 2 (40 nM) rapidly stimulated nuclear translocation of WOX1 and WOX2 in COS7 cells in a time-dependent manner. (b) In a timecourse experiment, stimulation of primary mink lung epithelial Mv1Lu cells with E 2 (40 nM) for various indicated times also induced phosphorylation and nuclear translocation of both p53 and WOX1. (c) dn-WOX1 abolished E 2 -induced nuclear translocation of WOX1 and p53. COS7 cells were transfected with a dn-WOX1 construct, GFP-dn-WOX1 (in pEGFP-C1) (Chang et al., 2003a) , or a control GFP construct (pEGFP-C1) by electroporation. After culturing for 48 h, the cells were stimulated with E 2 (40 nM) for 30 min. E 2 induced nuclear translocation of endogenous WOX1 in GFP-transfected cells, but not in the dn-WOX1-transfected cells. Expression of the ectopic GFP-dn-WOX1 or GFP in COS7 cells was observed by fluorescence microscopy (B60% positive). Representative data were from two experiments 17b-Estradiol activates WOX1/WWOXv1 N-S Chang et al cells was observed by fluorescence microscopy (B60% positive).
Upregulation and activation of WOX1 and family proteins positively correlate with progression of prostate form normal to hyperplasia, cancer and metastasis Both sex steroid hormones and hyaluronidases play important roles in the development of benign prostatic hyperplasia and prostatic adenocarcinoma (Lokeshwar and Rubinowicz, 1999; Lokeshwar et al., 2001; Patel et al., 2002; Marker et al., 2003) . Hyaluronidases PH-20, Hyal-1 and Hyal-2 induce the expression of WOX1 (Chang et al., 2001; Chang, 2002b) , suggesting a likely role of WOX1 in prostatic cancer and prostatic hyperplasia.
By immunohistochemistry, we examined protein expression in breast and prostate tissue sections using specific antibodies against (1) the conserved N-terminus of WOX1 family proteins (Chang et al., 2001) , (2) the unique C-terminus of WOX1 (Sze et al., 2004) , (3) the unique C-terminus of WOX2 (Sze et al., 2004) , and (4) Tyr33 phosphorylation in the first WW domain (p-WOX1) (Chang et al., 2003a) .
During the progression of prostate from normal to benign hyperplasia (hypertrophy), adenocarcinoma (cancer) and metastasis, significant upregulation of WOX1, WOX2 and family proteins (if present), along with their Tyr33 phosphorylation and nuclear translocation, was observed (see Supplementary  Figure 2 in the Supplementary Information). Shown in Figure 2 is the increased expression and Tyr33 phosphorylation of WOX1 family proteins (p-WOX1) during prostate cancer progression to a metastatic stage. At a hypertrophy stage, p-WOX1 was present mostly in perinuclear area. Nuclear translocation of p-WOX1 was shown at cancerous and metastatic stages ( Figure 2 , Table 1 , and Supplementary  Figure 2) .
Similarly, breast cancer progression from normal to a cancerous stage is also associated with upregulation of WOX1, WOX2 and family proteins (see Supplementary  Figure 3a and b in Supplementary Information). These observations are in agreement with other reports (Driouch et al., 2002; Watanabe et al., 2003) . However, nuclear translocation of WOX1, WOX2 and Tyr33-phosphorylated proteins did not occur effectively ( Figure 2 , Table 1 and Supplementary Figure 3a and b). Notably, significant downregulation or absent Figure 2 Tyr33-phosphorylated WOX1 (p-WOX1) does not undergo nuclear translocation effectively in breast cancer tissues. Increased expression, Tyr33 phosphorylation and nuclear translocation of WOX1 and family proteins (WWOXs) were observed during progression of prostate from normal to hypertrophy, cancerous and metastatic stages. Tyr33 phosphorylation was also increased during breast cancer development. However, nuclear translocation of p-WOX1 did not occur effectively. Significant downregulation of p-WOX1 was observed in metastatic breast cells, whereas this event did not occur in metastatic prostate cancer cells; Â 1000 magnification. In negative controls; nonimmune rabbit sera were used 17b-Estradiol activates WOX1/WWOXv1 N-S Chang et al expression of the WOX1 family proteins and their Tyr33 phosphorylation was observed in metastatic breast cancer cells ( Figure 2 and Table 1 ; also see Supplementary Figure 3a and b). A recent report also showed that WWOX and FHIT genes are inactivated coordinately in invasive breast carcinoma (Guler et al., 2004) . By immunofluorescence, WOX1 family proteins are shown to localize mainly in the mitochondria in the normal and breast cancer cells (see Supplementary  Figure 3c ). Also, WOX1 family proteins in the mitochondria were Tyr33 phosphorylated (Figure 3 ), suggesting that phosphorylation of WOX1 at Tyr33 is essential for its translocation to the mitochondria. Mitochondria were stained by using antibodies against mitochondrial integral proteins such as Hsp60 (Supplementary Figure 3c ) and COX4 (cytochrome c oxidase subunit 4) ( Figure 3 ).
Summarized in Table 1 is the comparison of the expression of WOX1, WOX2, and total family proteins (WWOXs), along with their Tyr33 phosphorylation and nuclear translocation, during the development of breast and prostate cancers. Furthermore, to confirm these observations, we determined the extent of WOX1 expression in adenocarcinoma of prostate, breast and lung by staining tissue microarray slides (from NCI). We determined that WOX1 expression was significantly increased (by 3-6-fold) in these nonmetastatic adenocarcinoma tissues, compared to normal subjects (30 cancer samples versus 10 controls).
E 2 stimulates WOX1 activation in androgen receptornegative DU145 cells
While the development of prostate and breast cancers requires sex steroid hormones, we determined whether E 2 induces WOX1 activation in breast and prostate cancer cells. Prostate DU145 cells are androgenresistant and negative for androgen receptors (AR) (Wollin et al., 1989) , and express mutant p53 (Isaacs et al., 1991) . These cells express low levels of mRNA for estrogen receptor b (ER-b), whereas the protein levels of ER-b are unknown (Lau et al., 2000; Linja et al., 2003) . Mutant p53 plays a role in generating hormoneresistance and hormone-independent growth in prostate LNCaP cancer cells (Burchardt et al., 2001 ; Nesslinger 
Scale: À/+, minimal expression; +, mild expression; ++, moderate expression; +++, abundant expression. Relative expression of WWOX/WOX1 family proteins (WWOXs) from each tissue section was determined by comparing to corresponding normal controls. Prostate cases: control, n ¼ 5; hypertrophy, n ¼ 5; cancer, n ¼ 5; metastatic cancer, n ¼ 5; breast cases: control, n ¼ 5; cancer, n ¼ 5, metastatic cancer, n ¼ 5. , 2003) . E 2 effectively reduced the cytosolic levels of WOX1 and its Tyr33 phosphorylation in DU145 cells (Figure 4a ). Also, it increased the nuclear levels of WOX1 and Tyr33 phosphorylation (Figure 4a ), indicating that E 2 activates WOX1 in these cells. E 2 increased nuclear translocation and phosphorylation of mutant p53 in these cells (Figure 4a ). The level of p53 is relatively higher than that of WOX1 in these cells (Figure 4a ). E 2 also induced ERK phosphorylation in both cytosolic and nuclear levels ( Figure 4a ). These effects are similar to those observed in COS7 cells (Figure 1a) .
Despite the absence of AR, androsterone, an androgen, activated WOX1 in the nucleus of DU145 cells (Figure 4b ). Androsterone also induced phosphorylation of ERK, but not p53, at the nuclear level (Figure 4b) . Together, the above observations clearly demonstrate that sex hormone-mediated WOX1 activation is independent of hormone receptors. E 2 could not activate WOX1 and WOX2 in ER-positive MCF7 cells Breast MCF7 cells are ER positive and express wildtype p53 (Coezy et al., 1982; Gartel et al., 2003) . Notably, E 2 could not activate WOX1, WOX2 and p53 in MCF7, as determined in both Western blotting and immunostaining (Figure 5a ). The concentrations of E 2 used in these experiments were increased, compared to the above experiments. These observations are in agreement with those findings that WOX1 and WOX2 did not translocate effectively to the nuclei in breast cancer cells from patients ( Figure 2 and Table 1 ).
Compared to that of WOX1, the p53 level was low in MCF7 cells (Figure 5a ).
Owing to alternative splicing, ER-negative breast MDA-MB-231 cells do not express the full-length mRNA coding for wild-type WOX1 (Driouch et al., 2002) . MDA-MB-435S cells express the full-length WOX1 mRNA (Driouch et al., 2002) . These cells are metastatic and have a dysfunctional p53 (Toillon et al., 2002; Gartel et al., 2003) , and express very low levels of wild-type WOX1 protein (Figure 5b ). These findings are in agreement with the observations from metastatic breast specimens, which expressed little or no WOX1 (Figure 2 ). E 2 could not effectively induce activation of WOX1 and ERK in these cells (Figure 5b ). E 2 induced phosphorylation of nuclear p53 in MDA-MB-231 but not in MDA-MB-435S cells (Figure 5b ). p53 levels in (Gangolli et al., 1997; Green et al., 1997; Gridley et al., 1998) . Mechanism of this regard is unknown. E 2 increased the levels of cytosolic WOX1 and p53, without inducing nuclear translocation of these proteins (see Supplementary Figure 4 in Supplementary Information). Also, E 2 could not induce Tyr33 phosphorylation of cytosolic WOX1, but reduced nuclear WOX1 phosphorylation in a dose-dependent manner. In agreement with other report (Watters et al., 1997) , E 2 induced ERK phosphorylation at both cytosolic and nuclear levels (Supplementary Figure  4 ). No E 2 -induced p53 phosphorylation was observed (Supplementary Figure  4) . p53 in these cells are conformationally altered and is resistant to stress-induced activation (Gaitonde et al., 2000; Wolff et al., 2001) .
Again, as shown above, our findings indicate that ER and AR are not involved in the hormone-induced WOX1 activation. Without Tyr33 phosphorylation, WOX1 could not undergo nuclear translocation (Chang et al., 2003a) . However, Tyr33-phosphorylated WOX1 could not translocate to the nuclei in breast cancer cells, suggesting the presence of cytosolic inhibitors that prevent E 2 -induced nuclear translocation of WOX1. E 2 induces complex formation and cotranslocation of p53/ WOX1 to the nuclei in COS7 fibroblasts, but not in MCF7 cells
We have shown that WOX1 physically interacts with p53 and JNK1 and the likely presence of a p53/WOX1/ JNK1 complex in vivo (Chang et al., 2003a) . Next, we investigated whether E 2 stimulates cotranslocation of the p53/WOX1/JNK1 complex to the nucleus. COS7 fibroblasts, cultured with 10% fetal bovine serum, were stimulated with E 2 for 30 min, followed by precipitating with protein A agarose beads conjugated with IgG antibodies against p-WOX1, p53 and JNK1, respectively. Precipitating with anti-JNK1 showed the presence of JNK1 with p53 and WOX1 in the precipitates from serum-stimulated COS7 cells, suggesting the presence of cytosolic p53/WOX1/JNK1 complex ( Figure 6a ). E 2 induced cotranslocation of WOX1 with p53, but not with JNK1, to the nucleus ( Figure 6a ). The nuclear WOX1 was Tyr33-phosphorylated ( Figure 6a ). Precipitating with p53 or p-WOX1 also showed presence of the p53/WOX1 complex in the nuclei of E 2 -treated COS7 cells (Figure 6a) .
In MCF7 cells, E 2 induced the complex formation of cytosolic p53 and WOX1, whereas WOX1 in this complex could not undergo nuclear translocation (Figure 6b ). These results are in agreement with the above observations that WOX1 is mainly present in the Figure 6 E2 induces cotranslocation of p53 and WOX1 to the nuclei of COS7 but not MCF7 cells. (a) COS7 fibroblasts, cultured overnight in the presence of 10% fetal bovine serum, were exposed to E 2 (40 nM) for 30 min, followed by processing immunoprecipitation using cytosolic and nuclear fractions (B500 mg protein) and protein A agarose beads conjugated with IgG antibodies against p53, JNK1, and p-WOX1, respectively. Precipitating with anti-JNK1 or anti-p53 resulted in the presence of JNK1 with p53 and WOX1 in the precipitates from serum-stimulated COS7 cells, suggesting presence of a cytosolic p53/WOX1/JNK1 complex. E 2 induced cotranslocation of WOX1 with p53, but not with JNK1, to the nucleus. Precipitating with p-WOX1 also showed presence of the p53/WOX1 complex in the nuclei. (b) In MCF7 cells, E 2 induced the complex formation of cytosolic p53 and WOX1, whereas WOX1 in this complex could not undergo nuclear translocation. IP, immunoprecipitation; IgH, IgG heavy chain 17b-Estradiol activates WOX1/WWOXv1 N-S Chang et al mitochondria of breast cancer cells from patients ( Figure 3) .
Discussion
By immunohistochemistry, we determined that progression of prostate from normal to hyperplasia, cancerous and metastatic stages positively correlate with upregulation and activation of WOX1 (WWOXv1), WOX2 (WWOXv2) and their family proteins (if present). In comparison, breast cancer development to a premetastatic stage is also associated with upregulation of these family proteins, whereas their nuclear translocation could not occur effectively in breast cells. Majority of the upregulated proteins are Tyr33-phosphorylated and located mainly in the mitochondria, suggesting that Tyr33 phosphorylation is essential for their translocation to the mitochondria. Interestingly, significant downregulation or absent expression of these family proteins is shown in metastatic breast cancer cells, but not in metastatic prostate cancer cells.
Mitochondrial localization of WOX1 has been shown in vivo. By electron microscopy, we have recently demonstrated that constant light induces translocation of WOX1 to the mitochondria of photoreceptors in rat eyes (Chen et al., 2004a, b) . These mitochondrial WOX1 proteins are also Tyr33-phosphorylated.
While the development of breast and prostate cancers is hormone-dependent, we discovered that E 2 activates WOX1, p53 and ERK in COS7 fibroblasts, primary lung epithelial cells, and AR-negative prostate DU145 cells, but not in ER-positive breast MCF7 cells. Androgen also activates WOX1 in DU145 cells. E 2 was shown to colocalize and cotranslocate with WOX1 to the nuclei in COS7 cells, as determined by immunofluorescence (data not shown). These observations suggest that estrogen and androgen are likely to bind to the NSYK motif in the C-terminus of WOX1, and that AR and ER are not involved in the E 2 -induced WOX1 activation.
Failure of sex hormones in inducing WOX1 nuclear translocation is shown in MCF7 and other breast cells. These findings are in agreement with the clinical findings that Tyr33-phosphorylated WOX1 is located mainly in the mitochondria and could not translocate to the nuclei effectively. The mechanisms by which estrogen and androgen fail to induce WOX1 nuclear translocation in breast cells are unknown. E 2 induced the binding of p53 with WOX1 and their nuclear translocation in COS7 cells. Nonetheless, E 2 -increased p53/WOX1 complex could not undergo nuclear translocation in MCF7 cells, suggesting presence of a blocker protein(s) that prevents nuclear translocation. We have shown that JNK1 binds and blocks cytosolic WOX1 activation (Chang et al., 2003a) . Whether JNK1 contributes a role to the failure of E 2 -stimulated WOX1 nuclear translocation in breast cancer cells remains to be determined. Other proteins such as p73, a p53 homologue (Aqeilan et al., 2004) , SIMPLE (PIG7) (Ludes-Meyers et al., 2004) and Tau (Sze et al., 2004 ) are known to bind WOX1. p73 and WOX1 appear to induce apoptosis synergistically (Aqeilan et al., 2004) . WOX1 binds Tau via its C-terminal SDR domain and is likely to play a critical role in regulating Tau hyperphosphorylation and formation of neurofibrillary tangles in vivo (Sze et al., 2004) . Whether SIMPLE (PIG7) regulates WOX1 function has not been determined (Ludes-Meyers et al., 2004) .
WOX1 is overexpressed in benign prostatic hyperplasia and prostatic cancer, as determined by immunohistochemistry and tissue microarray analysis. Similar results were also observed in adenocarcinomas of breast and lung. Most interestingly, metastatic breast cells in targeted organ sites have significantly reduced levels of WOX1 and p-WOX1. Whether this is related with alternative splicing of WWOX mRNA or alteration of WWOX gene is unknown. ER-negative breast MDA-MB-231 do not express the full-length mRNA coding for wild type WOX1, whereas MDA-MB-435S cells express the full-length WOX1 mRNA (Driouch et al., 2002) . These cells are metastatic and express very low levels of wild type WOX1 protein. The observations suggest that a blockade of translation of mRNA to protein occurs in MDA-MB-435S cells.
Silencing of WOX1 expression may be essential for cancer cell metastasis. That is, WOX1 protein may participate in inhibiting cancer cell metastasis. This notion is supported by the observations that distinct deleted regions on chromosome segment 16q23-24, encoding WWOX/FOR2/WOX1, are associated with metastases in prostate and breast cancers (Caligo et al., 1998; Elo et al., 1999; Li et al., 1999) .
Tyr33 phosphorylation of WOX1 is also significantly increased in the tissues of prostate and breast adenocarcinoma. However, majority of the phosphorylated WOX1 does not translocate to the nuclei. Indeed, a large portion of the phosphorylated WOX1 is present in the mitochondria, suggesting its role in homeostasis in these organelles. WOX1 possesses a conserved NSYK motif that may interact with estrogen and androgen (Chang et al., 2003b) . The increased Tyr33-phosphorylation suggests activation of WOX1 by sex hormones in vivo.
Interestingly, prolonged exposure of COS7 cells to E 2 for more than 24 h resulted in apoptosis of these cells (data not shown). Whether the induced apoptosis is related with nuclear translocation of the proapoptotic p53 and WOX1 is unknown. Under similar conditions, E 2 could not induce apoptosis of Mv1Lu and other cells tested in this study. Estrogen is generally considered to exert neuroprotection (Gangolli et al., 1997; Green et al., 1997; Gridley et al., 1998; Garcia-Segura et al., 2001; Wise, 2002) and protect breast tissues from apoptosis (Gompel et al., 2000; review) . However, at high doses estrogen may induce apoptosis (Song and Santen, 2003; review) . We do not exclude the possibility that at a physiologic concentration, WOX1 is antiapoptotic and essential for cell survival (Chang et al., 2003b) .
Functionally, ectopic p53 and WOX1 induce apoptosis in a synergistic manner (Chang et al., 2001 ).
Suppression of WOX1 by antisense mRNA or by dn-WOX1 abolishes p53 apoptosis (Chang et al., 2001 (Chang et al., , 2003a . Most strikingly, all the above tested cells, except SK-N-SH, demonstrate an inversed relationship between the expression of WOX1 and p53. That is, the levels of wild-type p53 are low in MCF7 and Mv1Lu epithelial cells, yet their expression of WOX1 is high. In contrast, expression of mutant p53 is increased in a variety of cancer cells, whereas their WOX1 levels are low. Knockdown of WOX1 expression by siRNA in L929 fibroblasts abolishes the expression of p53 and its transcriptional target p21 (Chang et al., unpublished) . These cells possess wild-type p53. Similarly, suppression of WOX1 expression by siRNA abrogates p53 and p21 expression in SK-N-SH cells, suggesting that WOX1 is involved in the regulation of p53 expression. Aqeilan et al. (2004) demonstrated that ectopic human WWOX binds ectopic p73. Whether endogenous p73 binds WWOX is not known. In their experiments, this ectopic WWOX did not bind ectopic p53. We could not estimate why both the overexpressed WWOX and p53 failed to interact. We show that stress stimuli and sex hormones increase the binding of WOX1 with p53. Thus, a likely scenario for the failure of p53/WWOX binding in the report of Aqeilan et al. is due to experiments performed under nonstressed conditions for cells.
Whether WOX1 possesses a dehydrogenase activity is not known and remains to be determined. Enzymes of the SDR-containing protein family have been shown to catalytically interact with estrogens and androgens (Filling et al., 2002; Kallberg et al., 2002) . For instance, 17-hydroxysteroid dehydrogenases (17-HSD) are important in regulating the biological potency of steroid hormones by catalysing oxidation or reduction at position 17 (Filling et al., 2001; He et al., 2001) . However, these enzymes could not translocate to the nuclei in response to sex hormones. E 2 -induced WOX1 nuclear translocation is related with the N-terminal NLS and two conserved phosphorylation sites at Tyr33 and Tyr61 in the WW domains (Chang et al., 2001 (Chang et al., , 2003a . In agreement with our previous observations (Chang et al., 2003a) , E 2 -induced Tyr33 phosphorylation is essential for WOX1 nuclear translocation. Whether E 2 induces Tyr61 phosphorylation is being determined in this laboratory.
Breast and prostate cancer cells develop sex hormoneindependent growth through unknown mechanisms. This development could be due to loss, truncation, or mutation of cell surface or nuclear ER and AR. WOX1 is a proapoptotic protein (Chang et al., 2001 (Chang et al., , 2003a . Failure of estrogen or androgen-mediated WOX1 nuclear translocation may allow cancer cell growth. That is, failure of WOX1 activation is likely to contribute to hormone-independent growth of breast and prostate cancer cells. Indeed, WOX1 can either suppress or enhance the functions of several transcription factors that are involved in growth regulation and apoptosis at the nuclear level (Pugazhenthi et al., unpublished) .
Materials and methods
Cell lines and chemicals
Cell lines maintained in our laboratory and used in these studies were monkey kidney COS7 fibroblasts, murine L929 fibrosarcoma cells, human neuroblastoma SK-N-SH cells, human prostate DU145 cells (AR negative) (Wollin et al., 1989) , and human breast MCF7 (ER positive) (Coezy et al., 1982) , MDA-MB-231 (ER negative) (Xu et al., 1996) , and MDA-MB-435S (ER negative) cells (Bronzert et al., 1982) . MCF7, MDA-MB-231 and MDA-MB-435S were gifts of Drs John Noti and Mary Cismowski of this Institute. Water-soluble E 2 (1,3,5[10]-estratriene-3,17b-diol; cyclodextrin-encapsulated), 6-ketoestradiol (1,3,5[10]-estratriene-3, 17b-diol-6-one), estriol (1,3,5[10]-estratriene-3,16a,17b-triol), and androsterone (5a-androstan-3a-ol-17-one) were purchased from Sigma.
cDNA expression constructs cDNA constructs for a murine wild-type and a dn-Wox1 were made in pEGFP-C1 vector (Clontech) (Chang et al., 2001 (Chang et al., , 2003a . The expressed proteins were tagged with an N-terminal enhanced green fluorescent protein (EGFP). This dn-WOX1 blocks p53-mediated apoptosis and anisomycin-mediated WOX1 phosphorylation, but could not inhibit JNK1 activation (Chang et al., 2003a) .
Antibodies and antibody production
We have generated antibodies against (1) an N-terminal segment (RLAFTVDDNPTKPTTRQRY) of murine WOX1 at amino acid #89-107 (Chang et al., 2001) , (2) Tyr33-phosphorylation at the first WW domain of murine WOX1 using a synthetic phosphopeptide (KDGWV p YYANH-TEEKT) at amino acid #28-42 (Chang et al., 2003a) , and (3) the first WW domain (amino acid #28-42) without Tyr33 phosphorylation (Chen et al., 2004b) . Additionally, murine Wox1 cDNA was subcloned in a pGEX2T vector (Amersham Pharmacia Biotech), and recombinant WOX1 protein tagged with glutathione-S-transferase (GST) was produced in bacteria and purified according to the manufacturer's instruction. Antibodies against recombinant GST-WOX1 protein were generated in rabbits as described (Chang et al., 2001 (Chang et al., , 2003a , using an EZ Antibody Production and Purification Kit from Pierce. The generated antisera were shown to interact with both GST and WOX1.
Additional antibodies used in Western blottings were against the following proteins: full-length p53 (FL-393; Santa Cruz Biotechnology), Tyr204-phosphorylated ERK (Santa Cruz Biotechnology), Ser15-phosphorylated p53 (Oncogene Sciences), JNK1 (Santa Cruz Biotechnology), and a-tubulin (Accurate Chemicals). Also, goat anti-human WWOX IgG antibodies (N-19) were gifts of Santa Cruz Biotechnology.
Western blotting and coimmunoprecipitation
Coimmunoprecipitation was performed as previously described (Chang et al., 2001 (Chang et al., , 2003a . Briefly, COS7 cells were treated with E 2 for various indicated times to activate WOX1. These cells were washed with ice-cold Tris-buffered saline (TBS; pH7.4) containing 50 mM EDTA (TBS/EDTA), and the cytosolic and nuclear fractions of these cells were prepared using NE-PER Nuclear and Cytoplasmic Extraction reagents (Pierce). Endogenous WOX1, JNK1 and p53 were captured by specific IgG antibodies against p-WOX1 (Chang et al., 2003a) , p53 (FL-393; Santa Cruz Biotechnology), or JNK1 (Santa Cruz Biotechnology) in the presence of protein A-agarose beads (Pierce). Proteins bound by the agarose beads were then washed with TBS/EDTA containing 0.5% NP-40, and analysed by SDS-PAGE and Western blotting using indicated antibodies.
Human prostate and breast tissues, immunohistochemistry and immunofluorescence
Medically and legally consent postmortem prostate tissues (five each) from patients with benign prostatic hypertrophy (BPH), prostatic adenocarcinoma, prostatic metastasis, or agematched normal prostate tissues were obtained from the autopsy service at the Department of Pathology, University of Colorado Health Sciences Center. Similarly, breast tissues (five each) from patients with normal breast, ductal adenocarcinoma, or metastatic cancer were examined. All tissues were processed and treated following standard histology protocols that include antigen retrieval, blocking of endogenous peroxidase and nonspecific antigen binding (Sze et al., 2004) . The tissue sections were incubated with aliquots of antibodies against the C-terminus of WOX1 or WOX2, the first WWdomain of WOX1, or the Tyr33-phosphorylated WOX1 (1 : 200 final dilution in TBS, pH 7.4) at 41C overnight. Aliquots of biotinylated secondary antibodies were then added. Color development was performed using an LSAB þ HRP kit (DAKO). In negative controls, tissue sections were stained with aliquots of prebled rabbit sera. Where indicated, synthetic peptides (100 mM) were premixed with the above-mentioned antisera (5 min at room temperature) prior to immunostaining.
Also, immunofluorescence was performed using breast and prostate tissue sections. Primary antibodies used in the immunofluorescence were against: (1) Hsp60 (Stressgen), (2) COX4 (Clontech), (3) WWOX (N-19) (Santa Cruz Biotechnology), and (4) Tyr33 phosphorylation in the first WW domain (p-WOX1) (Chang et al., 2003a, b) . Secondary antibodies were (1) anti-rabbit IgG FITC, (2) anti-goat IgG rodamine, and (3) anti-mouse IgG Texas Red.
Cancer tissue microarray
Multitumor tissue microarray slides were from the Tissue Array Research Program, National Cancer Institute. These slides were immunostained with antibodies against the Nterminal region of WOX1 (Chang et al., 2001) , and a secondary FITC-conjugated anti-rabbit IgG. Each tissue microarray slide contained a total of 500 sections of normal tissues, CNS tumors, melanoma, lymphoma, and cancers of ovarian, breast, colon, lung and prostate. Expression of WOX1 was quantified by the extent of emitted green fluorescence.
